NCT03972657: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 2 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03972657 |
|---|---|
| Title | A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 12, 2019 |
| Completion date | Nov. 15, 2027 |
| Required reporting date | Nov. 14, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |